The impact of peginterferon alpha-2a maintenance therapy on portal hypertension in patients with chronic hepatitis C virus infection and advanced fibrosis and cirrhosis enrolled in the HALT-C trial

Trial Profile

The impact of peginterferon alpha-2a maintenance therapy on portal hypertension in patients with chronic hepatitis C virus infection and advanced fibrosis and cirrhosis enrolled in the HALT-C trial

Completed
Phase of Trial: Phase II/III

Latest Information Update: 22 Mar 2017

At a glance

  • Drugs Peginterferon alfa-2a (Primary)
  • Indications Hepatitis C; Portal hypertension
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 Dec 2007 Status changed from recruiting to completed.
    • 23 Feb 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top